---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093321"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:22:11.172172+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross

## Summary
- Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.
- Cash, cash equivalents and short-term investments $336.1M, expected to fund operations through end of 2026.
- IPO with concurrent private placement raised $174.4M gross ($157.6M net).
- Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation; topline data mid-2025.
- Board member Terry-Ann Burrell to transition off board after Form 10-Q filing.

## SEC filing metadata
- accession: 0000950170-24-093321
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000095017024093321/0000950170-24-093321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000095017024093321/rapp-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093321
- JSON: https://secwatch.observer/filing/0000950170-24-093321.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.